Overview

Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment

Status:
Completed

Trial end date:
2015-05-13

Target enrollment:

Participant gender:

Summary

To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Gabapentin
gamma-Aminobutyric Acid